AstraZeneca PLC (NASDAQ:AZN) Short Interest Update

AstraZeneca PLC (NASDAQ:AZNGet Rating) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 10,820,000 shares, a growth of 39.4% from the March 31st total of 7,760,000 shares. Based on an average daily volume of 8,020,000 shares, the days-to-cover ratio is presently 1.3 days.

Shares of AstraZeneca stock opened at $66.40 on Friday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.16 and a quick ratio of 0.76. AstraZeneca has a 1 year low of $52.74 and a 1 year high of $71.70. The company has a market capitalization of $205.76 billion, a P/E ratio of -207.49, a P/E/G ratio of 1.26 and a beta of 0.48. The business has a 50 day moving average price of $64.54 and a 200 day moving average price of $60.59.

AstraZeneca (NASDAQ:AZNGet Rating) last issued its quarterly earnings data on Thursday, February 10th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.07. AstraZeneca had a return on equity of 27.48% and a net margin of 0.30%. The firm had revenue of $11.50 billion during the quarter, compared to the consensus estimate of $11.06 billion. During the same period in the previous year, the firm posted $0.54 EPS. The company’s quarterly revenue was up 55.2% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca will post 3.32 EPS for the current fiscal year.

The business also recently disclosed a semi-annual dividend, which was paid on Monday, March 28th. Investors of record on Friday, February 25th were given a dividend of $0.985 per share. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.45. This represents a dividend yield of 2.4%. The ex-dividend date was Thursday, February 24th. AstraZeneca’s payout ratio is currently -603.11%.

Institutional investors have recently modified their holdings of the stock. Thomas White International Ltd. raised its holdings in AstraZeneca by 5.9% in the 3rd quarter. Thomas White International Ltd. now owns 37,237 shares of the company’s stock valued at $2,237,000 after acquiring an additional 2,063 shares during the last quarter. Wellington Management Group LLP raised its holdings in AstraZeneca by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 53,145,564 shares of the company’s stock valued at $3,191,923,000 after acquiring an additional 4,526,346 shares during the last quarter. Haverford Trust Co raised its holdings in AstraZeneca by 10.6% in the 3rd quarter. Haverford Trust Co now owns 4,414 shares of the company’s stock valued at $265,000 after acquiring an additional 424 shares during the last quarter. Banco Santander S.A. raised its holdings in AstraZeneca by 172.3% in the 3rd quarter. Banco Santander S.A. now owns 21,730 shares of the company’s stock valued at $1,305,000 after acquiring an additional 13,750 shares during the last quarter. Finally, Pura Vida Investments LLC acquired a new position in AstraZeneca in the 3rd quarter valued at $3,003,000. Hedge funds and other institutional investors own 20.54% of the company’s stock.

A number of brokerages have weighed in on AZN. TheStreet raised AstraZeneca from a “c+” rating to a “b-” rating in a report on Thursday, March 10th. Barclays lifted their price objective on AstraZeneca from £115 ($146.57) to £120 ($152.94) in a report on Thursday, April 14th. Morgan Stanley lifted their price objective on AstraZeneca from £102 ($130.00) to £111 ($141.47) in a report on Thursday, April 21st. Deutsche Bank Aktiengesellschaft lifted their price objective on AstraZeneca from £105 ($133.83) to £115 ($146.57) in a report on Wednesday, April 6th. Finally, SVB Leerink boosted their price target on AstraZeneca from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, February 24th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $7,223.13.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.